Details for Patent: 8,217,082
✉ Email this page to a colleague
Title: | Reduced irritant enema for the treatment of inflammatory bowel disease (IBD) |
Abstract: | The present invention comprises packaged enemas for the treatment of Inflammatory Bowel Disease (IBD), having substantially pure 5-ASA as the active ingredient, with a liquid carrier medium having a material avoidance of bowel irritant substances, such as anti-oxidants for the 5-ASA active ingredient, including such sulfites as potassium metabisulfite, for example, and contained within a sealed and substantially oxygen-free barrier package, which may preferably be formed of a foil/polymer laminate, and which package contains or otherwise includes an oxygen scavenger, such as a an oxygen scavenging sachet. |
Inventor(s): | Venkataraman; Bala (Alpharetta, GA), Brown; Lindsey (Atlanta, GA), Patel; Daxa (Marietta, GA) |
Assignee: | Alaven Pharmaceutical, LLC (Marietta, GA) |
Filing Date: | Dec 10, 2009 |
Application Number: | 12/635,443 |
Claims: | 1. A packaged enema, comprising: a stable dosage suspension of 5-ASA contained within a substantially oxygen-free liquid carrier medium, said liquid carrier medium having a material avoidance of antioxidants for said 5-ASA; at least one application bottle containing said dosage suspension; a sealed, substantially oxygen-free barrier package containing therein said at least one application bottle containing said dosage suspension; and an oxygen scavenger disposed within said barrier package, wherein at least said barrier package prevents migration of oxygen into said dosage suspension upon prolonged storage. 2. The packaged enema of claim 1, wherein said dosage suspension comprises approximately 1 g. to approximately 4 g. of said 5-ASA disposed within approximately 20 ml to approximately 60 ml of said liquid carrier medium. 3. The packaged enema of claim 1, wherein said liquid carrier medium comprises potassium acetate, xanthan gum, carbomer, sodium benzoate, edetate disodium and purified water. 4. The packaged enema of claim 1, wherein said dosage suspension comprises a pH of approximately 3 to approximately 5. 5. The packaged enema of claim 1, wherein said barrier package is a pouch. 6. The packaged enema of claim 5, wherein said pouch is a foil/polymer laminate. 7. The packaged enema of claim 6, wherein said foil/polymer laminate is polyester/aluminum foil/linear low density polyethylene. 8. The packaged enema of claim 6, wherein said foil/polymer laminate further comprises at least one adhesive. 9. The packaged enema of claim 6, wherein said liquid carrier medium comprises potassium acetate, xanthan gum, carbomer, sodium benzoate, edetate disodium and purified water. 10. The packaged enema of claim 9, wherein said oxygen scavenger is contained within a sachet. 11. The packaged enema of claim 10, wherein said at least one application bottle is of sufficient flexibility to facilitate squeeze dispensing of said dosage suspension. 12. The packaged enema of claim 11, further comprising a substantially inert gas contained in at least one of said barrier package and said at least one application bottle. 13. The packaged enema of claim 12, wherein said barrier package, said sachet and said substantially inert gas prevent migration of oxygen into said dosage suspension upon prolonged storage. 14. The packaged enema of claim 13, wherein said substantially inert gas is nitrogen. 15. The packaged enema of claim 1, wherein said at least one application bottle is of sufficient flexibility to facilitate squeeze dispensing of said dosage suspension. 16. The packaged enema of claim 1, wherein said application bottle is formed from a malleable polymer. 17. The packaged enema of claim 1, wherein said oxygen scavenger is contained within a sachet. 18. The packaged enema of claim 17, wherein said sachet is disposed within said barrier package in substantially isolated disposition with regard to said dosage suspension. 19. The packaged enema of claim 17, wherein said sachet is disposed within said barrier package in substantially communicating disposition with regard to said dosage suspension. 20. The packaged enema of claim 1, further comprising a substantially inert gas contained in at least one of said barrier package and said at least one application bottle. 21. The packaged enema of claim 20, wherein said substantially inert gas is nitrogen. 22. The packaged enema of claim 1, wherein said barrier package prevents discoloration of said dosage suspension upon prolonged storage. 23. The packaged enema of claim 1, wherein said liquid carrier medium comprises at least one of a buffering agent, a thickening agent, a chelating agent, an anti-microbial, a viscosity adjusting agent, and purified water. 24. The packaged enema of claim 1, wherein said dosage suspension comprises approximately 4 g. of said 5-ASA disposed within approximately 60 ml of said liquid carrier medium. 25. A packaged enema consisting essentially of: a stable dosage suspension of 5-ASA contained within a substantially oxygen-free liquid carrier medium, said liquid carrier medium comprising potassium acetate, xanthan gum, carbomer, sodium benzoate, edetate disodium, and purified water, and said liquid carrier medium having a material avoidance of antioxidants for said 5-ASA; at least one application bottle containing said dosage suspension; a sealed, substantially oxygen-free barrier package containing therein said at least one application bottle containing said dosage suspension, said barrier package formed from a foil/polymer laminate; an oxygen scavenging sachet disposed within said barrier package; a substantially inert gas contained in at least one of said barrier package and said at least one application bottle, wherein said substantially inert gas is nitrogen, and wherein said barrier package, said oxygen scavenging sachet and said substantially inert gas prevent migration of oxygen into said dosage suspension upon prolonged storage. 26. A packaged enema consisting essentially of: a stable dosage suspension of 5-ASA contained within a substantially oxygen-free liquid carrier medium, said liquid carrier medium comprising at least one of a buffering agent, a thickening agent, a chelating agent, an anti-microbial, a viscosity adjusting agent, and purified water, and said liquid carrier medium having a material avoidance of antioxidants for said 5-ASA; at least one application bottle containing said dosage suspension; a sealed, substantially oxygen-free barrier package containing therein said at least one application bottle containing said dosage suspension; an oxygen scavenger disposed within said barrier package; a substantially inert gas contained in at least one of said barrier package and said at least one application bottle, and wherein said barrier package, said oxygen scavenger and said substantially inert gas prevent migration of oxygen into said dosage suspension upon prolonged storage. |